Barsky EE, et al. - The authors strived to ascertain the pharmacokinetic and pharmacodynamic profile of intravenous (IV) ceftaroline in patients with cystic fibrosis (CF). Mean ceftaroline half-life was 1.1 h in this cohort of CF patients, which was notably lower than the general population. In all patients, the dosing regimen studied, which exceeds the recommended dosing in the non-CF population, was adequate to achieve >60% time above the minimum inhibitory concentration (MIC).